NASDAQ:STOK - Stoke Therapeutics Stock Price, Forecast & News

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Stoke Therapeutics (NASDAQ:STOK) announced its earnings results on Tuesday, November, 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. View Stoke Therapeutics' Earnings History.

Stoke Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Stoke Therapeutics.

6 brokers have issued 12-month price targets for Stoke Therapeutics' stock. Their forecasts range from $30.00 to $46.00. On average, they expect Stoke Therapeutics' share price to reach $37.60 in the next twelve months. This suggests a possible upside of 29.7% from the stock's current price. View Analyst Price Targets for Stoke Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stoke Therapeutics.

News stories about STOK stock have been trending negative recently, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Stoke Therapeutics earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Stoke Therapeutics.

Stoke Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 849,400 shares, an increase of 5.3% from the October 31st total of 806,300 shares. Based on an average daily volume of 177,700 shares, the short-interest ratio is presently 4.8 days. Currently, 5.5% of the company's stock are sold short. View Stoke Therapeutics' Current Options Chain.

Some companies that are related to Stoke Therapeutics include HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Myokardia (MYOK), PTC Therapeutics (PTCT), Genmab A/S (GMAB), Uniqure (QURE), Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Deciphera Pharmaceuticals (DCPH), Amicus Therapeutics (FOLD), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Arena Pharmaceuticals (ARNA) and Heron Therapeutics (HRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Exelixis (EXEL), Nektar Therapeutics (NKTR), ACADIA Pharmaceuticals (ACAD), Agios Pharmaceuticals (AGIO), Aeglea Bio Therapeutics (AGLE), Akero Therapeutics (AKRO), Arcturus Therapeutics (ARCT), Arena Pharmaceuticals (ARNA), ArQule (ARQL) and Athenex (ATNX).

(STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics' lock-up period expires on Monday, December 16th. Stoke Therapeutics had issued 7,891,110 shares in its IPO on June 19th. The total size of the offering was $142,039,980 based on an initial share price of $18.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Stoke Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (3.11%), Millennium Management LLC (2.13%), State Street Corp (0.42%), Squarepoint Ops LLC (0.07%), Granite Point Capital Management L.P. (0.05%) and California State Teachers Retirement System (0.04%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP and Rtw Investments, Lp. View Institutional Ownership Trends for Stoke Therapeutics.

STOK stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Millennium Management LLC and Redmile Group LLC. View Insider Buying and Selling for Stoke Therapeutics.

STOK stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC, California State Teachers Retirement System, Barclays PLC and Strs Ohio. Company insiders that have bought Stoke Therapeutics stock in the last two years include Apple Tree Partners Iv, LP and Rtw Investments, Lp. View Insider Buying and Selling for Stoke Therapeutics.

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STOK stock can currently be purchased for approximately $28.98.

Stoke Therapeutics has a market capitalization of $948.52 million. Stoke Therapeutics employs 44 workers across the globe.View Additional Information About Stoke Therapeutics.

The official website for Stoke Therapeutics is http://www.stoketherapeutics.com/.

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]